Zydus Lifesciences Ltd Q4 FY26 Results

Summary

Zydus Lifesciences Limited reported strong financial performance for Q4 FY26 and the full fiscal year. Q4 FY26 saw revenue from operations climb by 16.2% year-over-year to Rs. 75,870 mn, while EBITDA increased by 20.2% to Rs. 25,544 mn, with margins expanding to 33.7%. For the full year FY26, revenues reached Rs. 2,71,484 mn, a 16.8% increase, and EBITDA grew by 20.1% to Rs. 84,751 mn, achieving a 31.2% margin. The company's adjusted net profit also saw robust growth of 14.6% for Q4 and 15.0% for the full year. Dr. Sharvil Patel, Managing Director, emphasized the strong close to FY26, delivering on revenue and profitability commitments, and expressed confidence in the pipeline to drive future growth while maintaining a strong balance sheet for further investments.

Key Highlights

1. 1

   Revenue from operations for Q4 FY26 increased by 16.2% year-over-year to Rs. 75,870 mn.

2. 2

   EBITDA for Q4 FY26 grew by 20.2% year-over-year to Rs. 25,544 mn, with the EBITDA margin improving by 110 bps to 33.7%.

3. 3

   Adjusted Net Profit for Q4 FY26 stood at Rs. 15,929 mn, marking a 14.6% increase compared to the previous year.

4. 4

   For the full year FY26, revenue from operations was Rs. 2,71,484 mn, representing a 16.8% growth over FY25.

5. 5

   Full year FY26 EBITDA rose by 20.1% to Rs. 84,751 mn, with an EBITDA margin of 31.2%, an 80 bps improvement year-over-year.

6. 6

   The Board recommended a dividend of 100% for FY 2025-26 and approved a share buyback for up to Rs. 11,000 mn at a price of Rs. 1,150 per share.